Thiol/Disulfide Homeostasis and the Multinational Society for Supportive Care in Cancer Risk Score in Febrile Neutropenia

Yıl 2025, Cilt: 8 Sayı: 1, 19 - 24, 29.03.2025

Çağdaş Yıldırım , Şervan Gökhan , Gül Pamukçu Günaydın , Mehmet Ergin , Fatih Tanrıverdi , Fatih Ahmet Kahraman , Alp Şener , Özcan Erel

https://doi.org/10.54996/anatolianjem.1517687

Öz

Aim: This study aims to determine the use of thiol/disulphide homeostasis parameters together with procalcitonin (PCT), C-reactive protein (CRP) and Multinational Association for Supportive Care in Cancer (MASCC) risk scoring system for the prediction of prognosis and mortality in the patients with febrile neutropenia presenting to the emergency department.

Material and Methods: The study was carried out prospectively on 53 patients with febrile neutropenia and 51 healthy subjects presenting to the emergency department. Thiol/disulphide homeostasis parameters, which are oxidative stress markers, were measured through a new method developed by Erel and Neşelioğlu. PCT and CRP were also measured. Patients were grouped in to high-risk and low-risk groups in terms of prognosis and mortality through MASCC scores.

Results: Mean values of disulphide/native thiol, CRP and PCT were found to be significantly higher in the patients having febrile neutropenia (p=0.029, p<0.001 and p<0.001, respectively). Mean values of disulphide/native thiol, CRP and PCT were found to be significantly higher in the high-risk patients (p=0.038, p=0.004, and p=0.002, respectively).

Conclusion: The use of thiol/disulphide homeostasis parameters, PCT and CRP together with the MASCC system may be used for the prediction of the prognosis in the patients with febrile neutropenia.

Anahtar Kelimeler

Febrile neutropenia, Thiol/disulphide homeostasis, oxidative stress, procalcitonin, c reactive protein

Etik Beyan

Approval was obtained from Ankara Yıldırım Beyazıt University Clinical Research Ethics Committee (Date: 14/06/2017 Number: 134).).

Destekleyen Kurum

There is no supporting institution.

Febril Nötropenide Tiyol/Disülfid Homeostazı ve Kanserde Destekleyici Bakım için Çok Uluslu Derneği Risk Skoru

Öz

Amaç: Bu çalışmada, acil servise başvuran febril nötropeni hastalarında tiyol / disülfid homeostaz parametreleri ile prokalsitonin (PCT), C-reaktif protein (CRP) ve Kanserde Destekleyici Bakım için Çok Uluslu Derneği (MASCC) risk skorlama sisteminin birlikte prognoz ve mortalitenin öngörülmesi için birlikte kullanımını belirlemeyi amaçlanmaktadır.

Gereç ve Yöntem: Çalışma prospektif olarak febril nötropeni tanısı alan 53 hasta ve acil servise başvuran 51 sağlıklı bireyüzerinde gerçekleştirildi. Oksidatif stres markerleri olan tiyol/ disülfid homeostaz parametreleri Erel ve Neşelioğlu tarafından geliştirilen yeni bir yöntemle ölçüldü. PCT ve CRP de ölçüldü. Hastalar MASCC skorları ile prognoz ve mortalite açısından yüksek riskli ve düşük riskli gruplara ayrıldı.

Bulgular: Febril nötropeni tanısı olan hastalarda disülfid / nativ tiyol, CRP ve PCT değerlerinin anlamlı derecede yüksek olduğu bulundu (sırasıyla p = 0,029, p <0,001 ve p <0,001). Disülfid / nativ tiyol, CRP ve PCT değerlerinin yüksek riskli hastalarda anlamlı olarak yüksek olduğu bulundu (sırasıyla p = 0,038, p = 0,004 ve p = 0,002).

Sonuç: Febril nötropeni tanısı alan hastalarda prognozun öngörülmesi için tiyol / disülfid homeostaz parametreleri, PCT ve CRP'nin MASCC sistemi ile birlikte kullanılabilir.

Anahtar Kelimeler

Febril nötropeni, Tiyol/disülfit homeostazı, oksidatif stres, prokalsitonin, c reaktif protein

Etik Beyan

Ankara Yıldırım Beyazıt Üniversitesi Klinik Araştırmalar Etik Kurulunun onayı alınmıştır (Tarih: 14/06/2017 Numara: 134).).

Destekleyen Kurum

Bu çalışma herhangi bir finansal destek almamıştır.

Kaynakça

• Adelberg DE, Bishop MR. Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am. 2009;27:311-331. doi:10.1016/j.emc.2009.01.005
• Wenneras C, Hagberg L, Andersson R, et al. Distinct Inflammatory Mediator Patterns Characterize Infectious and Sterile Systemic Inflammation in Febrile Neutropenic Hematology Patients. PLoS One. 2014;9(3):e92319. doi:10.1371/journal.pone.0092319
• Bille J. Laboratory diagnosis of infections in febrile neutropenic or immunocompromised patients. Int J Antimicrob Agents. 2000;16(2):87-89. doi:10.1016/s0924-8579(00)00211-9
• Juutialinen A, Hamalainen S, Pulkki K Kuittinen T, Nousiainen T, Koivula I. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leuk Lymphoma. 2011;52:2349-2355. doi:10.3109/10428194.2011.597904
• Buyukberber N, Buyukberber S, Sevinc A, Camci C. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol. 2009;26:55-61. doi:10.1007/s12032-008-9081-z.
• Persson L, Engervall P, Magnuson A, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004;36:365-371. doi:10.1080/00365540410020217.
• Kern WV, Heiss M, Steinbach G. Prediction of gram-negative bacteraemia in patients with cancer and febrile neutropenia by means of IL-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832-835. doi:10.1086/319207.
• Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47:326-332. doi:10.1016/j.clinbiochem.2014.09.026
• Sudhoff T, Giagounidis A, Karthaus M. Serum and plasma parameters in clinical evaluation of neutropenic fever. Antibiot Chemother. 2000;50:10-19. doi:10.1159/000059308
• Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents. 2002;20(1):1-9. doi:10.1016/s0924-8579(02)00047-x
• Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051. doi:10.1200/JCO.2000.18.16.3038
• Groitl B, Jakob U. Thiol-based redox switches. Biochim Biophys Acta. 2014;1844:1335-1343. doi:10.1016/j.bbapap.2014.03.007
• Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134:49-55. doi:10.1016/s0022-2143(99)90053-7
• Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection. 2008;36(5):396-407. doi:10.1007/s15010-008-7374-y.
• Wu CW, Wu JY, Chen CK, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23:2863-2872. doi:10.1007/s00520-015-2650-8
• Luz Fiusa MM, Costa Lima C, de Souza GR, et al. A high angiopoetin-2/angiopoetin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care. 2013;17:R169. doi:10.1186/cc12848
• Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18(4):283-285. doi:10.1007/s100960050277
• Yildiz H. Thiol/disulphide homeostasis in intensive care unit patients with sepsis and septic shock. Turk J Med Sci. 2020 Jun 23;50(4):811-816. doi: 10.3906/sag-1905-148.
• Dulisse B, Li X, Gayle JA, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013;16(6):720-735. doi:10.3111/13696998.2013.782034.
• Yetkin F, Senol E, Yalçın S, Haznedar R. The evaluation of procalcitonin as a diagnostic and prognostic marker of bacterial infections in febrile neutropenic patients. Klimik Dergisi. 2011;24(1):24-30. doi: 10.5152/kd.2011.05
• Coyne JC, Le Vivian BS, Brennan JJ, et al. Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department. Ann Emerg Med. 2017 Jun;69(6):755-764. doi: 10.1016/j.annemergmed.2016.11.007..
• Massaro KSR, Macedo R, de Castro BS, et al. Risk factors for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients? Infection. 2014;42:1023-1032. doi:10.1007/s15010-014-0685-2
• Ortega M, Rovira M, Almela M, de la Bellacasa JP, Carreras E, Mensa J. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant. 2004;33:741-744. doi:10.1038/sj.bmt.1704409
• Ayar G, Sahin S, Men Atmaca Y, Uysal Yazici M, Neselioglu S, Erel O. Thiol-disulphide homeostasis is an oxidative stress indicator in critically ill children with sepsis. Arch Argent Pediatr. 2019;117(3):143-148. doi:10.5546/aap.2019.eng.143
• Ha YE, Song JH, Kang WK, et al. Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer. 2011;19:1761-1767. doi:10.1007/s00520-010-1017-4
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:111-118.
• Combariza JF, Lombana M, Pino EL, Arango M. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer. 2015;23:1009-1013. doi:10.1007/s00520-014-2454-2
• Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10. Eur J Cancer Care. 2007;16:475-483. doi:10.1111/j.1365-2354.2007.00780.x
• Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer. 2013;21:2303-2308. doi:10.1007/s00520-013-1787-6
• Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile neutropenic cancer patients. Clin Microbiol Infect. 2006;12:212-216. doi:10.1111/j.1469-0691.2005.01297.x
• Rintala E, Irjala K, Nikoskelainen J. Value of measurement of C-reactive protein in febrile patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 1992;11:973-978. doi:10.1007/BF01967785
• Prat C, Sancho MJ, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49(9):1752-1761. doi:10.1080/10428190802258956